Coluracetam: what does this study show?
AF64A-treated mice received oral MKC-231 at 0.3, 1 or 3 mg/kg once daily for 11 days. Acute administration and other nootropic agents were also examined.
Repeated treatment improved working-memory performance at all tested doses. Acute administration did not significantly improve memory at the tested doses. Some repeated doses reversed hippocampal acetylcholine depletion.
A toxin-induced mouse model does not establish a human regimen, clinical efficacy or safety.
These findings apply to the population and methods described above.
What might this mean, and what would change the interpretation?
A toxin-induced mouse model does not establish a human regimen, clinical efficacy or safety.
What would clarify this: Controlled human safety and efficacy research would be needed before clinical conclusions.
Findings reviewed · abstract
Checked Sep 23, 2026 against the linked abstract. This reading note is not a formal risk-of-bias appraisal.